Clinical characteristics and outcomes of patients receiving outpatient parenteral antibiotic therapy in a Belgian setting: a single-center pilot study.

IF 1.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Acta Clinica Belgica Pub Date : 2020-08-01 Epub Date: 2019-04-25 DOI:10.1080/17843286.2019.1608396
Caroline Briquet, Olivier Cornu, Valerie Servais, Chloe Blasson, Bernard Vandeleene, Halil Yildiz, Annabelle Stainier, Jean Cyr Yombi
{"title":"Clinical characteristics and outcomes of patients receiving outpatient parenteral antibiotic therapy in a Belgian setting: a single-center pilot study.","authors":"Caroline Briquet,&nbsp;Olivier Cornu,&nbsp;Valerie Servais,&nbsp;Chloe Blasson,&nbsp;Bernard Vandeleene,&nbsp;Halil Yildiz,&nbsp;Annabelle Stainier,&nbsp;Jean Cyr Yombi","doi":"10.1080/17843286.2019.1608396","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Outpatient parenteral antibiotic therapy (OPAT) was not used in Belgium before 2013, except for patients with cystic fibrosis. Thus, we have performed a pilot study to evaluate clinical characteristics and outcomes of patient receiving OPAT in a Belgian setting.</p><p><strong>Methods: </strong>The study was a prospective observational single-center study of patients receiving OPAT between 1 September 2013 and 31 December, 2017.</p><p><strong>Results: </strong>We included 218 OPATs. The median age was 58 years and 71% were men. At the end of the treatment, 92% of the patients on OPAT were cured. Risk factors for treatment failure were obesity, diabetes and diabetic foot infections, longer duration of hospitalization before OPAT, and duration of OPAT >16 days. An average of 24 days of hospitalization per patient discharge was saved, which amounted to 5205 days saved during the project. During the OPAT and 30 days thereafter, 71 (32.6%) of patients were readmitted, but only 26 (12%) readmissions were directly related to OPAT. Risk factors for readmissions were diabetes and diabetic foot infections, endovascular infections, longer duration of hospitalization before OPAT, duration of OPAT >30 days, and history of hospitalizations in the year before OPAT. There were 2.3 intravenous catheter-related events per 1000 days of catheter use. Patients' level of satisfaction was high (99.5%).</p><p><strong>Conclusions: </strong>In this pilot study, OPAT is found to be efficacious in saving hospitalization's days, with a low rate of readmissions and complications and a high patients' level of satisfaction. We therefore conclude that OPAT is feasible and safe.</p><p><strong>Background: </strong>Outpatient parenteral antibiotic therapy (OPAT) was not used in Belgium before 2013, except for patients with cystic fibrosis. Thus, we have performed a pilot study to evaluate clinical characteristics and outcomes of patient receiving OPAT in a Belgian setting.</p><p><strong>Methods: </strong>The study was a prospective observational single-center study of patients receiving OPAT between 1 September 2013 and 31 December, 2017.</p><p><strong>Results: </strong>We included 218 OPATs. The median age was 58 years and 71% were men. At the end of the treatment, 92% of the patients on OPAT were cured. Risk factors for treatment failure were obesity, diabetes and diabetic foot infections, longer duration of hospitalization before OPAT, and duration of OPAT >16 days. An average of 24 days of hospitalization per patient discharge was saved, which amounted to 5205 days saved during the project. During the OPAT and 30 days thereafter, 71 (32.6%) of patients were readmitted, but only 26 (12%) readmissions were directly related to OPAT. Risk factors for readmissions were diabetes and diabetic foot infections, endovascular infections, longer duration of hospitalization before OPAT, duration of OPAT >30 days, and history of hospitalizations in the year before OPAT. There were 2.3 intravenous catheter-related events per 1000 days of catheter use. Patients' level of satisfaction was high (99.5%).</p><p><strong>Conclusions: </strong>In our study, OPAT is found to be efficacious in saving hospitalization's days, with a low rate of readmissions and complications and a high patients' level of satisfaction. We therefore conclude that OPAT is feasible and safe.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"275-283"},"PeriodicalIF":1.1000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1608396","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2019.1608396","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/4/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 6

Abstract

Background: Outpatient parenteral antibiotic therapy (OPAT) was not used in Belgium before 2013, except for patients with cystic fibrosis. Thus, we have performed a pilot study to evaluate clinical characteristics and outcomes of patient receiving OPAT in a Belgian setting.

Methods: The study was a prospective observational single-center study of patients receiving OPAT between 1 September 2013 and 31 December, 2017.

Results: We included 218 OPATs. The median age was 58 years and 71% were men. At the end of the treatment, 92% of the patients on OPAT were cured. Risk factors for treatment failure were obesity, diabetes and diabetic foot infections, longer duration of hospitalization before OPAT, and duration of OPAT >16 days. An average of 24 days of hospitalization per patient discharge was saved, which amounted to 5205 days saved during the project. During the OPAT and 30 days thereafter, 71 (32.6%) of patients were readmitted, but only 26 (12%) readmissions were directly related to OPAT. Risk factors for readmissions were diabetes and diabetic foot infections, endovascular infections, longer duration of hospitalization before OPAT, duration of OPAT >30 days, and history of hospitalizations in the year before OPAT. There were 2.3 intravenous catheter-related events per 1000 days of catheter use. Patients' level of satisfaction was high (99.5%).

Conclusions: In this pilot study, OPAT is found to be efficacious in saving hospitalization's days, with a low rate of readmissions and complications and a high patients' level of satisfaction. We therefore conclude that OPAT is feasible and safe.

Background: Outpatient parenteral antibiotic therapy (OPAT) was not used in Belgium before 2013, except for patients with cystic fibrosis. Thus, we have performed a pilot study to evaluate clinical characteristics and outcomes of patient receiving OPAT in a Belgian setting.

Methods: The study was a prospective observational single-center study of patients receiving OPAT between 1 September 2013 and 31 December, 2017.

Results: We included 218 OPATs. The median age was 58 years and 71% were men. At the end of the treatment, 92% of the patients on OPAT were cured. Risk factors for treatment failure were obesity, diabetes and diabetic foot infections, longer duration of hospitalization before OPAT, and duration of OPAT >16 days. An average of 24 days of hospitalization per patient discharge was saved, which amounted to 5205 days saved during the project. During the OPAT and 30 days thereafter, 71 (32.6%) of patients were readmitted, but only 26 (12%) readmissions were directly related to OPAT. Risk factors for readmissions were diabetes and diabetic foot infections, endovascular infections, longer duration of hospitalization before OPAT, duration of OPAT >30 days, and history of hospitalizations in the year before OPAT. There were 2.3 intravenous catheter-related events per 1000 days of catheter use. Patients' level of satisfaction was high (99.5%).

Conclusions: In our study, OPAT is found to be efficacious in saving hospitalization's days, with a low rate of readmissions and complications and a high patients' level of satisfaction. We therefore conclude that OPAT is feasible and safe.

在比利时接受门诊肠外抗生素治疗的患者的临床特征和结果:一项单中心试点研究。
背景:2013年之前,除了囊性纤维化患者外,比利时未使用门诊肠外抗生素治疗(OPAT)。因此,我们进行了一项试点研究,以评估比利时环境中接受OPAT的患者的临床特征和结果。方法:该研究是一项前瞻性观察性单中心研究,研究对象为2013年9月1日至2017年12月31日接受OPAT治疗的患者。结果:纳入218例opat。中位年龄为58岁,71%为男性。治疗结束时,92%接受OPAT治疗的患者痊愈。治疗失败的危险因素为肥胖、糖尿病及糖尿病足感染、OPAT前住院时间较长、OPAT持续时间>16天。每例出院患者平均节省住院时间24天,项目期间累计节省住院时间5205天。在OPAT期间及其后30天,71例(32.6%)患者再次入院,但只有26例(12%)患者再次入院与OPAT直接相关。再入院的危险因素为糖尿病及糖尿病足感染、血管内感染、手术前住院时间较长、手术持续时间>30天、手术前一年有住院史。每1000天有2.3例静脉留置管相关事件。患者满意度高(99.5%)。结论:在本初步研究中,发现OPAT可有效节省住院天数,再入院率低,并发症发生率低,患者满意度高。因此,我们得出结论,OPAT是可行和安全的。背景:2013年之前,除了囊性纤维化患者外,比利时未使用门诊肠外抗生素治疗(OPAT)。因此,我们进行了一项试点研究,以评估比利时环境中接受OPAT的患者的临床特征和结果。方法:该研究是一项前瞻性观察性单中心研究,研究对象为2013年9月1日至2017年12月31日接受OPAT治疗的患者。结果:纳入218例opat。中位年龄为58岁,71%为男性。治疗结束时,92%接受OPAT治疗的患者痊愈。治疗失败的危险因素为肥胖、糖尿病及糖尿病足感染、OPAT前住院时间较长、OPAT持续时间>16天。每例出院患者平均节省住院时间24天,项目期间累计节省住院时间5205天。在OPAT期间及其后30天,71例(32.6%)患者再次入院,但只有26例(12%)患者再次入院与OPAT直接相关。再入院的危险因素为糖尿病及糖尿病足感染、血管内感染、手术前住院时间较长、手术持续时间>30天、手术前一年有住院史。每1000天有2.3例静脉留置管相关事件。患者满意度高(99.5%)。结论:在我们的研究中,发现OPAT有效地节省了住院天数,再入院率和并发症发生率低,患者满意度高。因此,我们得出结论,OPAT是可行和安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica MEDICINE, GENERAL & INTERNAL-
CiteScore
3.50
自引率
0.00%
发文量
44
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信